Preparation method and application of soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein
Through soluble B lymphocyte stimulation of factor receptor 3 and adiponectin sphere fusion protein, the problem of the inability to reverse articular cartilage destruction in the prior art was solved, significantly improved the symptoms and bone destruction of rheumatoid arthritis, and provided a highly targeted and targeted And a safe and effective treatment plan.
Patent Information
- Application Number
- CN202411007595.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-25
AI Technical Summary
Existing treatments for rheumatoid arthritis cannot fundamentally reverse the damage of articular cartilage, resulting in disability and work ability disorders in RA patients, and the mechanism of cartilage destruction is unclear.
The soluble B lymphocyte stimulator factor receptor 3 and adiponectin fusion protein were used to obtain the corresponding sequence through cloning, and the fusion protein was expressed and purified for the treatment and prevention of rheumatoid arthritis.
It significantly reduces the arthritis score and swelling degree in AA rats, improves the symptoms of arthritis and bone damage, and has a good effect in treating rheumatoid arthritis.
Smart Images

Figure CN118949008A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a preparation method of a soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein and an application thereof. Background Art
[0002] Rheumatoid arthritis is a chronic, inflammatory, systemic autoimmune disease that affects multiple joints. In China, the incidence of RA is approximately 0.28%, and the rate of work disability caused by RA is as high as 48%, which has placed a serious burden on patients' families and society. The pathogenesis of RA is closely related to the combined effects of environmental and genetic factors, which causes the body's immune tolerance balance to be broken, and immune cells such as T cells, B cells, macrophages, and dendritic cells are abnormally activated, producing a variety of proinflammatory cytokines, matrix-degrading enzymes, and autoantibodies against self-antigens, ultimately leading to bone and cartilage destruction. Studies have shown that compared with bone tissue destruction, damage to articular cartilage tissue is more directly related to disability and work disability caused by RA. At present, the clinical treatment of RA mainly includes nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, corticosteroids, and other cell-targeted therapies, including T, B, and monocyte / macrophage targeted therapies. These treatments are mainly used to reduce joint inflammation, slow the progression of the disease, and maintain joint function as much as possible. Articular cartilage destruction is one of the main factors leading to disability and work impairment in RA patients, but the mechanism of RA cartilage destruction is still unclear, and current drug treatments cannot fundamentally reverse the cartilage destruction caused by RA. Therefore, further exploration of the key mechanisms mediating RA cartilage damage will provide a theoretical basis for the development of new therapeutic drugs that are highly targeted, safe and effective. Summary of the invention
[0003] In order to overcome the above-mentioned shortcomings of the prior art, the present invention provides a method for preparing a soluble B lymphocyte stimulating factor receptor 3 adiponectin globular fusion protein and its application.
[0004] A drug comprises a soluble B lymphocyte stimulator receptor 3 and adiponectin globular fusion protein; the sequence of the fusion protein comprises one or more of SEQ ID No. 1 or SEQ ID No. 2.
[0005] Application of soluble B lymphocyte stimulator receptor 3 and adiponectin bulb fusion protein in preparing a drug for treating rheumatoid arthritis; the sequence of the fusion protein includes one or more of SEQ ID No. 1 or SEQ ID No. 2.
[0006] Application of soluble B lymphocyte stimulator receptor 3 and adiponectin bulb fusion protein in the preparation of a drug for preventing rheumatoid arthritis; the sequence of the fusion protein includes one or more of SEQ ID No. 1 or SEQ ID No. 2.
[0007] Preferably, the adiponectin comprises a protein hormone.
[0008] Preferably, the adiponectin is derived from adipose tissue.
[0009] A method for preparing a soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein comprises the following steps:
[0010] The BAFF-R3 extracellular region coding sequence SEQ ID No.3 and the adiponectin globular region coding sequence SEQ ID No.4 were cloned;
[0011] The BAFF-R3 extracellular region and the adiponectin globular region were connected via a peptide chain, and the eBR3-gAD fusion protein expression sequence was inserted into the plasmid using endonucleases and DNA ligases;
[0012] The above plasmids were transfected into cells, and stable expression cell lines were screened;
[0013] The cell lines were cultured, the supernatant was collected, and the soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein was obtained by gel filtration and chromatography purification.
[0014] Preferably, the endonucleases include Xhol, Xbal and EcoRV.
[0015] Preferably, the plasmid is pET28a(+)-His.
[0016] Preferably, the cells into which the plasmid is transfected include one or more of CHO cells or HEK293 cells.
[0017] The beneficial effects of the present invention are as follows:
[0018] The rigidly connected eBR3-gAD fusion protein and the flexible connected eBR3-gAD fusion protein of the present invention significantly reduce the arthritis score and swelling degree of AA rats, improve the arthritis symptoms and bone destruction degree of AA rats, and have a good effect in treating rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0020] Figure 1 Modeling of eBR3-gAD fusion protein and prediction of its binding energy with BAFF.
[0021] Figure 2 Schematic diagram of eBR3-gAD-pET28a(+)-His recombinant plasmid and enzyme digestion results.
[0022] Figure 3 This is the result of expression identification of eBR3-gAD fusion protein.
[0023] Figure 4 The figure shows the SDS-PAGE result of affinity purification of eBR3-gAD fusion protein.
[0024] Figure 5 This is the SDS-PAGE result of eBR3-gAD fusion protein dialysis.
[0025] Figure 6 This is the effect of eBR3-gAD on arthritis swelling in AA rats.
[0026] Figure 7 This is the effect of eBR3-gAD on arthritis score and number of swollen joints in AA rats.
[0027] Figure 8 This is the effect of eBR3-gAD on the degree of bone destruction in AA rats.
[0028] Fig. 9 This is the effect of eBR3-gAD on joint pathological damage in AA rats.
[0029] Fig.10 This is the effect of eBR3-gAD on the organs of AA rats. DETAILED DESCRIPTION
[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0031] Example 1: Modeling of eBR3-gAD fusion protein and prediction of its binding energy with BAFF
[0032] Obtain the following coding sequences from the NCBI database (https: / / www.ncbi.nlm.nih.gov / ):
[0033] BAFFR extracellular part coding sequence SEQ ID No.3:
[0034] MRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQESVGAGAGEAALPLPGLL.
[0035] Adiponectin bulb coding sequence SEQ ID No.4:
[0036] AYVYRSAFSVGLETYVTIPNMPIRFTKIFYNQQNHYDGSTGKFHCNIPGLYYF
[0037] AYHITVYMKDVKVSLFKKDKAMLFTYDQYQENNVDQASGSVLLHLEVGDQ VWLQVYGEGERNGLYADNDNDSTTFTGFLLYHDTN.
[0038] The eBR3-gAD fusion protein (rigidly linked to EAAAK2) was successfully established using Alphafold v2.3.1 ( Figure 1 A) and eBR3-gAD fusion protein (flexible linker GGGGS) model ( Figure 1 B), Pymol and PRODIGY were further used to analyze and predict the binding energy of the multimer formed between the predicted eBR3-gAD fusion protein and BAFF protein. It was found that the binding constant of the eBR3-gAD fusion protein (rigidly connected to EAAAK2) and BAFF protein was 6.9e-10, and the binding constant of the eBR3-gAD fusion protein (flexibly connected to GGGGS) and BAFF protein was 9.2e-10, both of which were strong binding.
[0039] Example 2: eBR3-gAD recombinant plasmid design and enzyme digestion results
[0040] The eBR3-gAD fusion protein sequence was inserted into the pET28a(+)-His plasmid using endonucleases Xhol, Xbal, EcoRV and DNA ligase, and the enzyme digestion effect was detected by gel electrophoresis. The expression sequences of eBR3-gAD fusion protein (flexible connection GGGGS) and eBR3-gAD fusion protein (rigid connection EAAAK2) are as follows:
[0041] (1) The expression sequence of eBR3-gAD fusion protein (flexible linker GGGGS) is SEQ ID No. 1: MHHHHHHAYVYRSAFSVGLETYVTIPNMPIRFTKIFYNQQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLFKKDKAMLFTYDQYQENNVDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLYHDTNGGGGSMRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQESVGAGAGEAALPLPGLL.
[0042] (2) The expression sequence of eBR3-gAD fusion protein (rigidly linked to EAAAK2) is SEQ ID No. 2: MHHHHHHAYVYRSAFSVGLETYVTIPNMPIRFTKIFYNQQNHYDGSTGKFHCNIPGLYYFAYHITVYMKDVKVSLFKKDKAMLFTYDQYQENNVDQASGSVLLHLEVGDQVWLQVYGEGERNGLYADNDNDSTFTGFLLYHDTNEAAAKEAAAKMRRGPRSLRGRDAPAPTPCVPAECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQESVGAGAGEAALPLPGLL.
[0043] The digestion results showed that the expected size of DNA fragments ( Figure 2 )
[0044] Example 3: Expression and identification of eBR3-gAD fusion protein
[0045] Select a single clone and culture it in 5 tubes of LB medium at 37℃ until the bacterial OD600 is 0.6-0.8, add IPTG to a final concentration of 0.5mM, culture at 37℃ for 4h, centrifuge, collect the bacteria and prepare samples, and analyze by SDS-PAGE and Western Blot; add IPTG to the 4 tubes of culture after the inoculated seed bacteria are cultured until the bacterial OD600 is 0.6-0.8 to the final concentration of 0.2mM and 1mM, respectively, and culture at 37℃ and 15℃ 220rpm for 4h and 16h, respectively, to induce the expression of fusion protein, and prepare samples for SDS-PAGE analysis under each condition; centrifuge the bacterial solution of each condition in the previous step to collect the bacteria, break it (Tris-NaCl buffer), prepare samples of the supernatant precipitate, and analyze it by SDS-PAGE. The expression identification results of eBR3-gAD fusion protein showed that after the sample was induced, eBR3-gAD fusion protein (flexible connection GGGGS) ( Figure 3 A) and eBR3-gAD fusion protein (rigidly linked to EAAAK2) ( Figure 3 B) expression.
[0046] Example 4: Affinity purification of eBR3-gAD fusion protein
[0047] The best clone strain was expanded and cultured in 2L LB medium at 37°C until OD600=0.6-0.8, and then induced at 15°C for 16h to collect the bacteria; the bacteria were collected by centrifugation, resuspended, and ultrasonically disrupted; the best clone strain was expanded and cultured in 2L LB medium at 37°C until OD600=0.6-0.8, and then induced at 15°C for 16h to collect the bacteria; the Ni was assembled 2+ The protein was purified using HisTrap protein purification column. Equilibration buffer: PBS (pH7.4), washing buffer: PBS (pH7.4 with 20mM and 50mM imidazole), elution buffer: PBS (pH7.4 with 500mM imidazole), and the liquid flow rate was 1mL / min. An appropriate amount of the effluent was taken for SDS-PAGE analysis. The results of affinity purification of eBR3-gAD fusion protein SDS-PAGE showed that eBR3-gAD fusion protein (flexible connection GGGGS) ( Figure 4 A) and eBR3-gAD fusion protein (rigidly linked to EAAAK2) ( Figure 4 B) expression, the protein is soluble.
[0048] Example 5: eBR3-gAD fusion protein concentration
[0049] The eluted sample was added to an ultrafiltration tube (retaining 10KD protein) for centrifugal concentration (4°C, 3500×g, 20min), filtered for sterilization, and stored at -80°C. The results of SDS-PAGE dialysis of eBR3-gAD fusion protein showed that the eBR3-gAD fusion protein (flexible connection GGGGS) could be obtained by affinity purification through SDS-PAGE detection ( Figure 5 A) and eBR3-gAD fusion protein (rigidly linked to EAAAK2) ( Figure 5 B), protein product purity>90%.
[0050] Comparative Example 6:
[0051] Experimental method: After one week of adaptive feeding, male SD rats (180±20g) were randomly divided into normal group and AA control group, with 7 rats in each group. BCG was inactivated at 80℃ and added to Freund's incomplete adjuvant to fully emulsify and mix to make Freund's complete adjuvant (10mg / ml). 0.1mL of Freund's complete adjuvant was subcutaneously injected into the left sole of each rat in the AA control group to induce arthritis to construct AA rats.
[0052] Example 6: Effect of eBR3-gAD on Arthritis in AA Rats
[0053] Experimental methods: After one week of adaptive feeding, male SD rats (180±20g) were randomly divided into eBR3-gAD-F treatment group, eBR3-gAD-R treatment group and methotrexate (MTX) treatment group, with 7 rats in each group. BCG was inactivated at 80℃ and added to Freund's incomplete adjuvant to fully emulsify and mix to make Freund's complete adjuvant (10mg / ml). 0.1mL of Freund's complete adjuvant was injected subcutaneously into the left sole of each rat in the treatment group to induce arthritis to construct AA rats. On the 11th, 14th, 17th, 20th, 23rd and 26th days after modeling, the rats in the eBR3-gAD fusion protein treatment group were treated with eBR3-gAD-F or eBR3-gAD-R by intra-articular injection, and the rats in the positive control group were treated with 0.75mg / kg MTX by gavage. On the 29th day after administration, the secondary side joints of AA rats were photographed, and the arthritis symptoms were observed macroscopically and images were taken.
[0054] Experimental results: Typical images of the secondary side joints of AA rats are shown in Figure 6 , compared with the normal group, the joints of the rats in the AA model group were significantly swollen, while compared with the rats in the AA control group, the joint swelling of the rats in the eBR3-gAD-F, eBR3-gAD-R and MTX treatment groups was significantly improved.
[0055] Comparative Example 7:
[0056] Experimental method: After one week of adaptive feeding, male SD rats (180±20g) were randomly divided into a normal group and an AA control group, with 7 rats in each group. BCG was inactivated at 80℃ and added to Freund's incomplete adjuvant to fully emulsify and mix to prepare Freund's complete adjuvant (10mg / ml). In the control group, 0.1mL of Freund's complete adjuvant was subcutaneously injected into the left sole of each rat to induce arthritis to construct AA rats.
[0057] Example 7: Effect of eBR3-gAD on arthritis index and number of swollen joints in AA rats
[0058] Experimental method: AA rat modeling and grouping were the same as in Example 6. On days 9, 12, 15, 18, 21, 23, 25, 27, and 29 after AA rat modeling, arthritis index scores and joint swelling number scores were performed every 2 to 3 days to observe the secondary lesions of each group of rats. The scoring criteria for arthritis index scores and joint swelling number scores are as follows:
[0059] (1) Scoring criteria for the arthritis index: 0 points for normal without redness or swelling; 1 point for erythema and mild swelling of the ankle joint; 2 points for erythema and mild swelling from the ankle joint to the metatarsal joint or metacarpal joint; 3 points for erythema and moderate swelling from the ankle joint to the metatarsophalangeal joint or metacarpal joint; 4 points for erythema and severe swelling from the ankle joint to the metatarsophalangeal joint.
[0060] (2) Scoring criteria for joint swelling: no swelling: 0 points; slight swelling of the toe joints: 1 point; swelling of the little toe joints and toes: 2 points; swelling of the paw below the ankle joint: 3 points; swelling of the entire paw including the ankle joint: 4 points.
[0061] Experimental results: See Figure 7 At different time points, eBR3-gAD-F, eBR3-gAD-R and MTX treatment reduced the arthritis index and number of swollen joints in AA rats. On the 29th day, compared with the AA model group, the arthritis index and number of swollen joints in the eBR3-gAD-F treatment group were significantly reduced (P < 0.01 or P < 0.001), and the arthritis index and number of swollen joints in the eBR3-gAD-R and MTX treatment groups were also significantly reduced (P < 0.05 or P < 0.01). The above results show that intra-articular injection of eBR3-gAD fusion protein can significantly improve the arthritis index and number of swollen joints in AA rats, that is, it effectively alleviates the symptoms of secondary joint lesions in AA rats.
[0062] Comparative Example 8:
[0063] Experimental method: After one week of adaptive feeding, male SD rats (180±20g) were randomly divided into a normal group and an AA control group, with 7 rats in each group. BCG was inactivated at 80℃ and added to Freund's incomplete adjuvant to fully emulsify and mix to prepare Freund's complete adjuvant (10mg / ml). In the control group, 0.1mL of Freund's complete adjuvant was subcutaneously injected into the left sole of each rat to induce arthritis to construct AA rats.
[0064] Example 8: Effect of eBR3-gAD on bone destruction in AA rats
[0065] Experimental method: AA rats were modeled and grouped as in Example 6, and Micro-CT was used to take bone images of the secondary ankle joint of the rats.
[0066] (1) μCT scanning
[0067] All sampled specimens were fixed and then scanned with Micro-CT. The scanning parameters were: X-ray tube current 200μA, voltage 85KV, scanning the entire object, scanning resolution 10.133799μm, exposure time 384ms, scanning angle 180 degrees. The phantom was scanned and calibrated under the same conditions. The original image was obtained after scanning.
[0068] (2) μCT reconstruction
[0069] Use the 3D reconstruction software Bruker SkyScan to reconstruct the selected area of the original image. Before reconstruction, preview the reconstructed image. In order to reduce image artifacts and achieve the best reconstruction effect, adjust the reconstruction parameters and set them to the following values: Smoothing = 3 (smoothing), Beam-hardening = 5 (light intensity), Ring artifacts = 30% (ring tail shadow) and other parameters. After the parameters are set, edit and select the specified folder to start image reconstruction.
[0070] Experimental results: see Figure 8Compared with the normal group, the ankle joints of the rats in the AA control group were significantly swollen, the bones of the joints were severely eroded, and the bone was destroyed; compared with the AA control group, eBR3-gAD-F, eBR3-gAD-R and MTX treatments can effectively eliminate ankle swelling, inhibit bone erosion and bone destruction. Further analysis was performed on the percentage bone volume (BV / TV), bone surface / volume ratio (BS / BV), bone surface density (BS / TV), trabecular pattern factor (Tb.Pf), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb. The results showed that compared with the normal group, the bone volume percentage (BV / TV), bone surface density (BS / TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N) of the AA control group were significantly decreased (P < 0.05 or P < 0.001), while the bone surface / volume ratio (BS / BV), trabecular pattern factor (Tb.Pf) and trabecular separation (Tb.Sp) were significantly increased (P < 0.001). eBR3-gAD-R and MTX treatments significantly increased bone volume percentage (BV / TV), bone surface density (BS / TV) and trabecular number (Tb.N) (P<0.001), and significantly decreased bone surface / volume ratio (BS / BV), trabecular pattern factor (Tb.Pf) and trabecular separation (Tb.Sp) (P<0.001). eBR3-gAD-F and MTX treatments significantly increased trabecular thickness (Tb.Th) (P<0.05 or P<0.001). The above results indicate that eBR3-gAD fusion protein can effectively reduce the degree of bone destruction in AA rats.
[0071] Comparative Example 9:
[0072] Experimental method: After one week of adaptive feeding, male SD rats (180±20g) were randomly divided into a normal group and an AA control group, with 7 rats in each group. BCG was inactivated at 80℃ and added to Freund's incomplete adjuvant to fully emulsify and mix to prepare Freund's complete adjuvant (10mg / ml). In the control group, 0.1mL of Freund's complete adjuvant was subcutaneously injected into the left sole of each rat to induce arthritis to construct AA rats.
[0073] Example 9: Effects of eBR3-gAD on joint pathological damage in AA rats
[0074] Experimental method: AA rat modeling and grouping were the same as in Example 6. On the 29th day, the ankle joints were collected after anesthetizing the rats, fixed with 4% paraformaldehyde for 48 hours, decalcified with EDTA for 4 weeks, and finally embedded in paraffin and sliced. The paraffin sections of the ankle joints were stained with hematoxylin-eosin (H&E) by trained observers in a blinded manner.
[0075] H&E staining steps: After the paraffin sections were baked at 56℃ for 2h, they were first dewaxed and hydrated, that is, the paraffin in the sections was removed by xylene, then the sections were put into distilled water through high concentration to low concentration alcohol; then H&E staining was performed, the sections that had been put into distilled water were placed in hematoxylin solution for staining for 10min, differentiated in 1% hydrochloric acid alcohol for 10s, rinsed with running water for 15min, then stained with eosin for 2min, and rinsed with running water 3 times; then dehydrated and transparent, 90% alcohol dehydration was repeated twice, each for 1min; 95% alcohol dehydration was repeated twice, each for 1min; 100% alcohol dehydration was repeated twice, each for 1min; xylene transparent treatment was performed for 3min, repeated 3 times; finally, it was sealed with gum and observed under a microscope after drying.
[0076] The H&E staining results were pathologically scored from five aspects: synovial cell proliferation, inflammation, pannus, bone erosion, and cell erosion. See Table 1 for details.
[0077] Table 1 Ankle joint pathology scoring table
[0078]
[0079]
[0080] Experimental results: H&E staining detected the pathological results of the rat ankle joint tissue. Fig.10 As shown. The ankle joints of rats in the normal group did not show any inflammation or cartilage damage. The excessive proliferation of synovial cells in AA rats led to narrowing of the joint cavity, and a large number of immune cells eroded the joint capsule, accompanied by a large range of pannus formation sites, obvious cartilage erosion and a large number of leukocytes aggregation. The treatment of eBR3-gAD-F and eBR3-gAD-R significantly inhibited the abnormal proliferation of synovial cells, inflammation of joint tissue and inflammatory cell infiltration, pannus formation and damage to bone tissue. Pathological scoring showed that compared with the AA group, eBR3-gAD-F and eBR3-gAD-R treatment significantly inhibited synovial hyperplasia, inflammation, pannus, bone erosion and cell erosion (P < 0.01 or P < 0.001). The above results suggest that intra-articular injection of eBR3-gAD fusion protein can significantly inhibit the abnormal proliferation of synovial fibroblasts, reduce bone destruction, and effectively alleviate the condition of AA rats.
[0081] Comparative Example 10:
[0082] Experimental method: After one week of adaptive feeding, male SD rats (180±20g) were randomly divided into a normal group and an AA control group, with 7 rats in each group. BCG was inactivated at 80℃ and added to Freund's incomplete adjuvant to fully emulsify and mix to prepare Freund's complete adjuvant (10mg / ml). In the control group, 0.1mL of Freund's complete adjuvant was subcutaneously injected into the left sole of each rat to induce arthritis to construct AA rats.
[0083] Example 10: Effects of eBR3-gAD on AA rat organs
[0084] Experimental method: AA rat modeling and grouping were the same as in Example 6. After the experiment, rats in each group were killed and the heart, liver, spleen, lung, and kidney tissues were gently removed with ophthalmic scissors. Each organ was fixed with 4% paraformaldehyde for 48 hours, then embedded in paraffin and sliced. The paraffin sections of each organ were stained with hematoxylin-eosin (H&E) by trained observers in a blinded manner, and typical images were taken. The specific steps are shown in Example 9.
[0085] Experimental results: The results are as follows Figure 5 As shown, intra-articular injection of eBR3-gAD-F and eBR3-gAD-R had no significant effect on the heart, liver, spleen, lung, kidney and other organs of AA rats.
[0086] The above results show that intra-articular injection of eBR3-gAD fusion protein can significantly improve the arthritis index, number of swollen joints, arthritis symptoms and bone destruction of AA rats, and has no obvious effect on other organs. It is a potential drug for the treatment of rheumatoid arthritis.
[0087] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0088] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.
Claims
1. A drug, characterized in that It comprises a soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein; the sequence of the fusion protein comprises one or more of SEQ ID No.1 or SEQ ID No.
2.
2. Use of soluble B lymphocyte stimulator receptor 3 and adiponectin globular fusion protein in the preparation of a drug for treating rheumatoid arthritis; the sequence of the fusion protein includes one or more of SEQ ID No.1 or SEQ ID No.
2.
3. Use of soluble B lymphocyte stimulator receptor 3 and adiponectin globular fusion protein in the preparation of a drug for preventing rheumatoid arthritis; the sequence of the fusion protein includes one or more of SEQ ID No. 1 or SEQ ID No.
2.
4. The use according to claim 2, characterized in that: The adiponectin comprises a protein hormone.
5. The use according to claim 2, characterized in that: The adiponectin is derived from adipose tissue.
6. A method for preparing a soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein, characterized in that: The following steps are involved: The BAFF-R3 extracellular region coding sequence SEQ ID No.3 and the adiponectin globular region coding sequence SEQ ID No.4 were cloned; The BAFF-R3 extracellular region and the adiponectin globular region were connected via a peptide chain, and the eBR3-gAD fusion protein expression sequence was inserted into the plasmid using endonucleases and DNA ligases; The above plasmids were transfected into cells, and stable expression cell lines were screened; The cell lines were cultured, the supernatant was collected, and the soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein was obtained by gel filtration and chromatography purification.
7. The method for preparing the soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein according to claim 6, characterized in that: The endonucleases include Xhol, Xbal and EcoRV.
8. The method for preparing the soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein according to claim 6, characterized in that: The plasmid is pET28a(+)-His.
9. The method for preparing the soluble B lymphocyte stimulating factor receptor 3 and adiponectin globular fusion protein according to claim 6, characterized in that: The cells into which the plasmid is transfected include one or more of CHO cells or HEK293 cells.
Citation Information
Patent Citations
Application of optimized TACI (Transmembrane Activator and CAML Interactor)-Fc fusion protein in preparation of medicaments for treating rheumatoid arthritis
CN102085367A
Method for rapid screening of modified tumor necrosis factor receptor II-adiponectin globular-site fusion protein and application thereof
CN102690353A
Novel receptor nucleic acids and polypeptides
CN104311658A
Soluble tumour necrosis factor receptor II-
CN1752108A
Novel receptor nucleic acids and polypeptides
US20040072188A1
